Advaxis Inc Cmn Stk (ADXS) 8.56 $ADXS Advaxis Announces

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 1:10 AM

Advaxis Inc Cmn Stk (ADXS) 8.56 $ADXS

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 8.56 (-0.26)

Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 8.56 (-0.26)

Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 8.56 (-0.26)

UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.56 (-0.26)

Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.56 (-0.26)

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 8.56 (-0.26)

Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 8.56 (-0.26)

AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 8.56 (-0.26)

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 8.56 (-0.26)

Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 8.56 (-0.26)

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 8.56 (-0.26), MRK: 56.81 (-0.37)

Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 8.56 (-0.26)

Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 8.56 (-0.26)

UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 7:08AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.56 (-0.26)

Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.56 (-0.26)

Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
GlobeNewswire - Mon Mar 21, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was published online March 18, 2016 in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
ADXS: 8.56 (-0.26)

Advaxis to Present at Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to present on Wednesday, March 16, 2016 at 4:20 p.m. EDT at the 2016 Barclays Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida.
ADXS: 8.56 (-0.26)

Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors
GlobeNewswire - Fri Mar 11, 8:05AM CST
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Gregory Mayes, Executive Vice President and Chief Operating Officer, has been elected to the Company's Board of Directors.
ADXS: 8.56 (-0.26)

Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA
GlobeNewswire - Wed Mar 09, 6:05AM CST
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, and SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), today announced that the companies have entered into a five-year exclusive supply agreement. Under the terms of the agreement, SGI-DNA will manufacture for Advaxis synthetic DNA which will be used in Advaxis' personalized Listeria monocytogenes (Lm)-based immunotherapy, known as MINE(TM) (My Immunotherapy Neo-Epitopes).
ADXS: 8.56 (-0.26)

Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer
GlobeNewswire - Mon Mar 07, 6:05AM CST
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced dose administration for the first patient in the expansion phase of an ongoing Phase 2 clinical trial of its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).
ADXS: 8.56 (-0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Alogent's Unify Snags Award for Innovation and Impact

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

FirstDigital Expands Fiber Network in Utah and Arizona

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Zephyr's Alto Hood: Redefining Kitchen Versatility

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...